May 28 2012
Medivir AB (OMX:MVIR), a research-based pharmaceutical company focused
on infectious diseases, announced today that a phase I clinical trial
has been initiated with its investigational drug, MIV-711, a cathepsin K
inhibitor for the treatment of bone disorders characterized by excessive
bone resorption such as osteoporosis, osteoarthritis and bone metastases.
Maris Hartmanis, CEO of Medivir commented, "This first in man study of
Medivir's MIV-711 is an important step in our effort to develop new
treatment options for patients with bone related diseases. The study
will provide us with crucial biomarker information reflecting both bone
and cartilage turnover. Based on this data we will be able to make a
fast and informed decision regarding the continued development of
MIV-711 to the market."
MIV-711 is a potent and selective reversible inhibitor of cathepsin K, a
protease essential for bone destruction. MIV-711 is being developed as a
new therapy in disease states where a reduction in cathepsin K activity
would be advantageous.
In this first in human study, MIV-711 will be administered as single
ascending oral doses to healthy volunteers, followed by repeated once
daily doses for 7 days, with the aim to explore the safety, tolerability
and pharmacokinetics. In addition effect on biomarkers relevant for bone
and cartilage degradation will be followed. MIV-711 will also be studied
in postmenopausal women following once daily oral dosing for 14 days.
The design of the study will allow Medivir to explore how MIV-711
affects biomarkers known to be relevant for measuring bone and cartilage
turnover. It will also provide the company with valuable information
regarding potential therapeutic dose levels to be used in future
studies. The results from this study are expected in the first quarter
of 2013.
Blackcurrant supplements show promise in preventing bone density loss in post-menopausal women